MedTrace Logo

Efficacy of 1072nm Infrared Stimulation on Executive Functioning in Dementia

NCT01059877 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2018-09-27

Study results available
· View outcomes & findings →

Summary

This study will employ a double-blind, placebo-controlled approach to assess the effect of 1072nm infrared (IR) phototherapy on the behavioral and cognitive symptoms associated with early and mid-stage dementia.

Conditions

Interventions

DEVICE

1072nm infrared Photobiomodulation

1072nm infrared light delivering 2.6 Joules (2.6J)/sq cm over a 6 minute treatment period.

DEVICE

Photobiomodulation SIMULATED

Device mounted and procedure followed but with no stimulation.

Sponsors & Collaborators

  • Maculume Ltd.

    collaborator INDUSTRY

  • Quietmind Foundation

    lead OTHER

Principal Investigators

  • Marvin H Berman, Ph.D · Quietmind Foundation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01059877 on ClinicalTrials.gov